FDA Approved Reminyl® for the Treatment of Mild AD
Quick Links
On February 28, 2001, the U.S. Food and Drug Administration (FDA) approved Reminyl® (galantamine hydrobromide) for the treatment of mild to moderate Alzheimer's disease. Data from placebo-controlled, double-blind clinical trials involving more than 2,650 patients show that Reminyl can have a beneficial effect on patients' daily function and ability to think. Developed by the Janssen Research Foundation, a wholly owned subsidary of Johnson & Johnson, and under a codevelopment and licensing agreement with the UK-based Shire Pharmaceuticals Group plc., Reminyl has been approved in 21 other countries to date. The drug will be available by prescription in the U.S. in May in 4 mg, 8 mg, or 12 mg tablets. Common side effects of the drug are gastrointestinal in nature, with a small percentage of patients experiencing nausea, vomiting, anorexia, diarrhea and weight loss.—Hakon Heimer
References
No Available References
Further Reading
No Available Further Reading
Annotate
To make an annotation you must Login or Register.
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.